The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation.

[1]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[2]  Xiaoxi Yao,et al.  Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. , 2017, Journal of the American College of Cardiology.

[3]  G. Lip,et al.  Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study , 2017, British Medical Journal.

[4]  D. Singer,et al.  Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. , 2016, Journal of the American College of Cardiology.

[5]  H. Mizuno,et al.  European Society of Cardiology (ESC) Annual Congress Report From Rome 2016. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[6]  L. See,et al.  Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation. , 2016, Journal of the American College of Cardiology.

[7]  G. Lip,et al.  Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study , 2016, British Medical Journal.

[8]  L. See,et al.  Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation , 2016, Stroke.

[9]  Mark Levenson,et al.  Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation , 2015, Circulation.

[10]  T. Chao,et al.  Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. , 2014, Journal of the American College of Cardiology.

[11]  M. Zoni-Berisso,et al.  Epidemiology of atrial fibrillation: European perspective , 2014, Clinical epidemiology.

[12]  Yu-Chieh Su,et al.  A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. , 2014, Kidney international.

[13]  P. Austin.  The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.

[14]  Lane F Burgette,et al.  A tutorial on propensity score estimation for multiple treatments using generalized boosted models , 2013, Statistics in medicine.

[15]  M. Hori,et al.  Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[16]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[17]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[18]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[19]  G. Lip,et al.  Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. , 2010, Age and ageing.

[20]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[21]  T. Tsoi,et al.  The Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Atrial Fibrillation , 2005, Cerebrovascular Diseases.

[22]  J. You,et al.  Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? , 2005, British journal of clinical pharmacology.

[23]  R B D'Agostino,et al.  Stroke severity in atrial fibrillation. The Framingham Study. , 1996, Stroke.

[24]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[25]  JCSJointWorkingGroup.  Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[26]  Chun-Yuh Yang,et al.  Epidemiological features of CKD in Taiwan. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.